K36 Therapeutics Inc

K36 Therapeutics, Inc. develops biopharmaceutical therapies for oncology applications. The Company conducts clinical trials for multiple myeloma and prostate cancer, develops selective inhibitors, and advances translational research in epigenetic modulation. K36 Therapeutics Inc serves cancer patients with unmet medical needs in the United States, Canada, and Europe.